Therapeutic Challenges to End-Stage Kidney Disease in a Patient with Tetralogy of Fallot

Ken Ohara, Tetsu Akimoto, Takuya Miki, Naoko Otani, Taro Sugase, Takahiro Masuda, Takuya Murakami, Toshimi Imai, Shin-ichi Takeda, Yasuhiro Ando, Shigeaki Muto and Daisuke Nagata

Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Shimotsuke-Shi, Tochigi, Japan.

ABSTRACT: In this report, we describe the case of an end-stage kidney disease patient with tetralogy of Fallot (TOF). A 33-year-old female with TOF was admitted to our hospital with complaints of general fatigue and appetite loss probably due to uremic milieu. She was ultimately treated with peritoneal dialysis (PD) with a favorable clinical course. TOF patients with chronic kidney disease are not exceptional, although the currently available information regarding the association between TOF and renal failure severe enough to require dialysis treatment is limited. We also discuss the complex processes of how and why PD was selected as a mode of chronic renal replacement therapy in this case.

KEYWORDS: end-stage kidney disease, peritoneal dialysis, tetralogy of Fallot, cyanotic nephropathy

Introduction

Tetralogy of Fallot (TOF) is a cyanotic congenital cardiac defect characterized by pulmonary outflow tract stenosis or obstruction, ventricular septal defect (VSD), overriding aortic root, and right ventricular hypertrophy.1 Left without surgical correction, the overall survival was poor and over 90% of the patients die by 40 years of age.2,3 There are some subsets of TOF patients with advanced chronic kidney disease (CKD); however, the association between TOF and renal failure severe enough to require dialysis treatment has been rarely reported in the literature.4,5 In this report, we describe the case of an end-stage kidney disease patient with TOF. We also discuss the complex processes of how and why peritoneal dialysis (PD) was selected as a mode of chronic renal replacement therapy in this case. The patient has given her written consent for publication of this report.

Case Report

A 33-year-old female with TOF managed by palliative surgery was admitted to our hospital with complaints of general fatigue and appetite loss at the end of December 2013. She was noted to be cyanosed at birth and had undergone Blalock-Taussig shunt at 2 years of age and palliative right ventricular outflow tract reconstruction, which is a procedure used to enlarge the ventricular outflow tract and main pulmonary artery, without inducing the closure of the concurrent VSD,6 at 4 years of age. There was no known family history of congenital cardiac disease. At 24 years of age, the patient’s serum creatinine (sCr) levels were increased at approximately 1.3 mg/dL, and her sCr levels thereafter continued to increase gradually, but slowly. In 2012, at 32 years of age, she became hypertensive, and her sCr levels were approximately 3.1 to 3.4 mg/dL with 3+ for urine protein when the additional surgical correction for closure of the VSD was planned. She was then referred to our hospital. According to the clinical pictures and renal sonographic findings, which showed decreases in the renal long axis dimensions (right: 80 mm, left: 85 mm) with grade II renal cortex echogenicity, the patient was diagnosed with CKD7 and subjected to contemporary and comprehensive renal care. Despite the successful control of her blood pressure to the ranges of 130–140/70–80 mmHg with losartan potassium and azelnidipine, her renal function steadily worsened during the last year, and she finally became aware of the symptoms at the end of December 2013 when her sCr and blood urea nitrogen (BUN) levels elevated up to 8.25 and 99 mg/dL, respectively. As a result, she was admitted for further workup. A physical examination completed on this admission revealed the patient to be alert. The patient’s blood pressure was 134/59 mmHg, her pulse was 78 beats/minute, and her temperature was 37.0 °C. Although the patient’s oxygen saturation was 85% while she breathed ambient air, a chest X-ray film demonstrated neither an accumulation of fluid nor a sign of pulmonary infiltrates. There were no rashes or lymphadenopathy, and no petechiae were found. A laboratory evaluation revealed
the following results: white blood cell count, 9,000/µL; red blood cell count, 407 × 10⁸/µL; hemoglobin (Hb), 12.1 g/dL; hematocrit, 36.4%; platelet count, 19.5 × 10⁹/µL; BUN, 111 mg/dL; sCr, 8.03 mg/dL; total protein, 7.7 g/dL; albumin, 4.7 g/dL; sodium, 139 mmol/L; potassium (K), 5.3 mmol/L; chloride, 108 mmol/L; calcium (Ca), 10.5 mg/dL; phosphorus (P), 7.2 mg/dL; aspartate aminotransferase, 13 U/L; alanine aminotransferase, 12 U/L; C-reactive protein, 0.02 mg/dL; and brain natriuretic peptide, 55.4 pg/mL. Her urine was 3+ for protein and + for occult blood and contained 1.3 g of protein in a 24-hour specimen, while the patient’s creatinine clearance was 5.02 mL/minute. Transthoracic echocardiography disclosed a perimembranous VSD (maximum diameter of 21 mm), a bidirectional shunt with left-to-right shunting (2.55 m/second) predominance, and well contracting left ventricle (LV) with an LV ejection fraction of 63.8% (Fig. 1A), while chest computed tomography (CT) scans demonstrated right pulmonary artery stenosis (Fig. 1B). The patient was subjected to a transient session of hemodialysis (HD) treatment with repeated femoral vein puncture before hospital days 2 and 14, during which time she began to feel well along with the decline in her sCr level. Finally, a Tenckhoff PD catheter was placed on hospital day 17 through a classic transverse surgical incision with a favorable postoperative course. PD using two daily exchanges (1.5 L of Midperiq³ × 2, Terumo Co..) with a total dwell of 12 hours was then initiated (Fig. 2). At the 1-year follow-up, the patient is still doing well with a daily urine output of approximately 1,100 to 1,300 mL. Considering the current therapeutic guidance for PD adequacy, her solute clearance status expressed in terms of $\text{Kt/V}_{\text{urea}}$, where $\text{K}$ is the clearance of urea, $t$ is the treatment duration, and $V$ is the urea distribution volume, also appears to be favorable (a total $\text{Kt/V}_{\text{urea}}$: 1.9 [peritoneal $\text{Kt/V}_{\text{urea}}$: 0.8, residual renal $\text{Kt/V}_{\text{urea}}$: 1.1]).

**Discussion**

Along with the decline in the mortality of patients with congenital heart diseases, it has become clear that various types of disturbed physiologies occur beyond the cardiovascular system. Chronic renal insufficiency is one such late complication, and it may also be common even in adult subjects after obtaining the palliation of previous TOF. Several morphological alterations, including glomerular enlargement, mesangial hypercellularity, glomerular capillary congestion, and segmental glomerular sclerosis, have been focused on as pathologic bases of the disease. In the current patient, the absence of any pathological information precluded us from precisely evaluating the cause of end-stage kidney disease. However, we believe that numerous conditions, including previous surgical palliation and long-standing cyanotic conditions, could play a role in the establishment of her renal manifestations. Alternatively, or in addition, the long-term use of various analgesics for relieving menstrual pain and a tension headache, which was revealed by our thorough clinical interview, might have played a role in our patient through their nephrotoxic nature. Thus, the combination of TOF and CKD may not be surprising; however, the clinical significance of the current patient should be evaluated carefully in terms of the impact of the circulation disturbance due to cardiac anomaly on the therapeutic managements for end-stage kidney disease, including the choice of dialysis modality.

For many patients with end-stage kidney disease, a renal transplant is the treatment of choice as it replicates the standard renal physiology much more closely than dialysis treatments and offers an improved quality of life as well as survival benefits. Despite the high risk of cardiac death before and after renal transplantation, patients with cardiac disease or who are at high risk for cardiac disorders are still eligible for this procedure. Moreover, it has been stated that patients with severe irreversible heart dysfunction should not be listed for kidney transplantation alone, while there may be select patients who are candidates for combined heart–kidney transplants. The scarce information regarding renal transplantation among patients with un repaired congenital heart disease precludes us from precisely evaluating the validity of such a strategy in the current case; however, the lack of readily available cadaveric or living renal transplantation in a timely manner, which leaves many subjects requiring dialysis, obliged us to start dialysis treatment.

Considering the pathophysiologic characteristics of TOF, we felt that avoiding the use of dialysis catheters as a means of either temporary or permanent vascular access for HD and the execution of periodic HD with peripheral vascular access should be mandatory in the current patient. Indeed, these devices may predispose patients with TOF to the detrimental pathologies such as pulmonary embolism, septicemia, infectious endocarditis, and paradoxical embolism, although the available literature has seldom discussed pulmonary embolism in patients with TOF. We must also recognize that in patients with an intrinsic cardiac anomaly, the creation of peripheral vascular access may result in severe
Therapeutic challenges to end-stage kidney disease

Otherwise, it should be noted that bacteremia is less frequent in PD patients than in chronic HD patients with endovascular catheter, and no reports on infectious endocarditis in PD patients were available, despite the fact that septicemia is not exceptional in PD subjects. Therefore, PD does not appear to be an additional risk of infectious endocarditis among patients with end-stage kidney disease.

Alternatively, or in addition, the therapeutic nature of PD, including minimal variation in the intravascular volume status, reduction in cardiovascular stress, avoidance of peaks and troughs in uremic toxins, arrhythmia prevention, and the better preservation of residual renal function, also encouraged us to promote the procedure as a good modality of renal replacement therapy for the current patient.

There may be substantial variation in the type and intensity of managements provided to end-stage kidney disease patients with congenital heart disease, stemming from the uncertainty of the advantages and disadvantages of renal care in this population. A lack of prospective data suggests that numerous therapeutic decisions among such subjects are potentially empirical. Indeed, only a few anecdotal reports describing patients with TOF who began dialysis treatments during the observation periods for the disease are available.

At present, our patient appears to tolerate the PD program well with two daily dialysate exchanges; however, the validity of our strategy should be determined only when more experience with additional cases similar to ours has been accumulated. Thus, the establishment of an optimal management program for end-stage kidney disease patients with congenital heart disease should be a matter requiring continuous and careful attention.

Author Contributions
Drafted the manuscript: KO, TA. Contributed to the acquisition of the clinical data: TMiki, NO, TS, TMasuda, TMurakami, TI, ST. Provided a detailed review of the...
1. Apitz C, Webb GD, Redington AN. Tetralogy of Fallot. Lancet. 2009;374(9699):1462–71.

2. Bertrandou EG, Blackstone EH, Hazelrig JB, Turner ME, Kirklin JW. Life expectancy without surgery in tetralogy of Fallot. Am J Cardiol. 1978;42(3):458–66.

3. Gerlis LM, Ho SY, Sheppard MN. Longevity in the setting of tetralogy of Fallot: survival to the 84th year. Cardiol Young. 2004;14(6):664–6.

4. Yang X, Freeman LJJ, Ross C. Unoperated tetralogy of Fallot: case report of a natural survivor who died in his 73rd year; is it ever too late to operate? Postgrad Med J. 2005;81(952):133–4.

5. Dimopoulos K, Diller GP, Koltsida E, et al. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. Circulation. 2008;117(18):2210–8.

6. Okiya Y, Miwa S, Kurohara K, et al. Palliative reconstruction of right ventricular outflow tract in tetralogy with hypoplastic pulmonary arteries. Ann Thorac Surg. 1990;49(5):775–9.

7. Ozmen CA, Akin D, Bilek SU, Bayrak AH, Senturk S, Nazaroglu H. Ultrasound as a diagnostic tool to differentiate acute from chronic renal failure. Clin Nephrol. 2010;74(1):46–52.

8. Kaneda H, Kaneda F, Shimoyamada K, Sakai S, Takahashi M. Repeated femoral vein puncturing for maintenance haemodialysis vascular access. Nephrol Dial Transplant. 2003;18(8):1631–8.

9. Lo WK, Bargman JM, Burkart J, et al; ISPD Adequacy of Peritoneal Dialysis Working Group. Guideline on targets for solute and fluid removal in adult patients on chronic peritoneal dialysis. Perit Dial Int. 2006;26(5):520–2.

10. Akimoto T, Shizaki K, Sugase T, et al. The relationship between the soluble Klotho protein and the residual renal function among peritoneal dialysis patients. Clin Exp Nephrol. 2012;16(3):442–7.

11. Buelow MW, Dall A, Bartz PJ, et al. Renal dysfunction is common among adults after palliation for previous tetralogy of Fallot. Pediatr Cardiol. 2013;34(1):651–9.

12. Flanagan MF, Hourihan M, Keane JF. Incidence of renal dysfunction in adults with cyanotic congenital heart disease. Am J Cardiol. 1991;68(4):403–6.

13. Gupte PA, Vaiderswar P, Kandalkar BM. Cystic nephropathy—a morphometric analysis. Congen Heart Dis. 2014;9(4):280–5.

14. Elseviers MM, De Broe ME. Analgesic nephropathy: is it caused by multi-analgesic abuse or single substance use? Drug Saf. 2000;23(1):15–24.

15. Goodlad C, Brown E. The role of peritoneal dialysis in modern renal replacement therapy. Postgrad Med J. 2013;89(1056):584–90.

16. Devine PA, Aaising EC. Renal replacement therapy should be tailored to the patient. Practitioner. 2014;258(1768):19–22.

17. Le A, Wilson R, Dousek K, et al. Prospective risk stratification in renal transplant candidates for cardiac death. Am J Kidney Dis. 1994;24(1):65–71.

18. Knoll G, Cockrell S, Blydt-Hansen T, et al; Kidney Transplant Working Group of the Canadian Society of Transplantation. Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation. CMAJ. 2005;173(10):S1–25.

19. Li W, Somerville J. Infective endocarditis in the grown-up congenital heart (GUCH) population. Eur Heart J. 1998;19(1):166–73.

20. Fortun J, Centella T, Martin-Davila P, et al. Infective endocarditis in congenital heart disease: a frequent community-acquired complication. Infection. 2013;41(4):167–74.

21. Severi HF, Van Rijk PP, Van Isselt JW, Mali WP, Koomans HA, Blaakmeer PJ. Pulmonary embolism after thrombolysis of hemodialysis grafts. J Am Soc Nephrol. 1997;8(9):1458–63.

22. Manian FA. Vascular and cardiac infections in end-stage renal disease. Am J Med Sci. 2003;325(2):43–60.

23. Hsieh HS, Liao HT, Wei CJ, Tang RC. Indwelled femoral vein non-cuffed, double-lumen hemodialysis catheter complicated by pulmonary thromboembolism. Clin Nephrol. 2004;62(2):162–4.

24. Ram R, Swarnalatha G, Rakesh Y, Josytha M, Prasad N, Dakshinamurty KV. Right atrial thrombus due to internal jugular vein catheter. Hemodial Int. 2009;13(3):261–5.

25. Sadjadi SA, Sharif-Hassanabadi M. Fatal pulmonary embolism after hemodialysis vascular access declotting. Am J Case Rep. 2014;15:172–5.

26. Pinzani EA, Faial S, Schussler JM. Catastrophic paradoxical embolus after hemodialysis access thrombectomy in a patient with a patent foramen ovale. Int Urol Nephrol. 2013;45(4):1215–7.

27. Windecker S, Stortecky S, Meier B. Paradoxical embolism. J Am Coll Cardiol. 2014;64(4):403–15.

28. Wu IL, Tseng JC. Pulmonary embolism in a patient of tetralogy of Fallot: a diagnostic challenge. Am J Emerg Med. 2015;33(6):865.e5–865.e6.

29. Tanaka H, Kakuta T, Fukagawa M. Overt intracardiac shunt flow after arteriovenous graft placement. Clin Exp Nephrol. 2013;17(4):592–3.

30. Powe NR, Jaar B, Furth SL, Hermann J, Briggs W. Septicemia in dialysis patients: incidence, risk factors, and prognosis. Kidney Int. 1999;55(3):1081–90.

31. Fernández-Ceán J, Álvarez A, Burguez S, Baldovinos G, Larre-Borges P, Cha M. Infective endocarditis in chronic haemodialysis: two treatment strategies. Nephrol Dial Transplant. 2002;17(12):2236–20.

32. Thodis E, Pasadakikie, Vargemize V, Oreopoulos DG. Peritoneal dialysis: better than, equal to, or worse than hemodialysis? Data worth knowing before choosing a dialysis modality. Perit Dial Int. 2001;21(1):25–35.

33. Shahab I, Khanha R, Nolph KD. Peritoneal dialysis or hemodialysis? A dilemma for the nephrologist. Adv Perit Dial. 2006;22:180–5.

34. Kobayashi M, Mataga T, Machida K, et al. Chronic renal failure caused by long-term cyanosis in a patient with tetralogy of Fallot. Tohoku J Exp Med. 1994;179:1055–61. [in Japanese, Abstract in English]

35. Shimizu A, Takei T, Moriyama T, et al. A case study of initiating hemodialysis in a patient with tetralogy of Fallot (TOF). Adv Perit Dial. 2004;20(4):412–7.

36. Vignolo G, Neri L, Barbieri S. Incremental peritoneal dialysis: effects on the choice of dialysis modality, residual renal function and adequacy. Kidney Int. 2008;73(suppl 108):S52–5.